Supernus bags early-stage CNS drug for $15M upfront in renewed epilepsy R&D efforts
A few years into marketing their two epilepsy drugs, the neurology and psychiatry experts at Supernus Pharma are going back to the drawing board with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.